Skip directly to site content Skip directly to search


Español  Other Languages


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
 Search
		×
			Vaccines site
			Vaccines site
				All CDC
				Submit
			For a full list of topics:A-Z Index
			Advanced Search
		Advanced Search


Advisory Committee on Immunization Practices (ACIP)








ACIP Presentation Slides: February 22-24, 2023 Meeting						Print
																Related Pages
										On This Page
			Mpox VaccineRespiratory disease surge, Fall 2022, United StatesInfluenza VaccinePneumococcal VaccinesMeningococcal VaccinesPolio VaccineRSV Vaccines - Pediatric/MaternalRSV Vaccines - AdultChikungunya VaccineDengue VaccinesVaricellaCOVID-19 Vaccines
Note: These files are not yet 508
Slides will be added as they become available.
February 22, 2023
Welcome & Introductions
IntroductionDr. G Lee
Dr. M WhartonMpox Vaccine
Introduction [16 pages]Dr. Pablo Sanchez
Epidemiology of mpox during 2022 outbreak in the United States [18 pages]Dr. Sascha Ellington
JYNNEOS Vaccine Safety [26 pages]Dr. Jonathan Duffy
JYNNEOS Vaccine Effectiveness [21 pages]Dr. Anna Chard
Mpox vaccine acceptability and uptake from cross-sectional surveys [26 pages]Dr. Kevin P. Delaney
Interim Clinical Considerations [12 pages]Dr. Rosalind Carter
EtR: Use of JYNNEOS during mpox outbreaks [48 pages]Dr. Agam RaoRespiratory disease surge, Fall 2022, United States
Dr. José R. RomeroInfluenza Vaccine
Introduction [3 pages]Dr. Keipp Talbot
U.S. Influenza activity update [7 pages]Dr. Lisa Grohskopf
Preliminary 2022-23 influenza vaccine effectiveness: CDC networks [25 pages]Ms. Samantha Olson, Dr. Nathaniel Lewis, Dr. Mark Tenforde
Preliminary 2022-23 influenza vaccine effectiveness: Wisconsin [15 pages]Dr. Huong McClean
Published Estimates of LAIV Effectiveness [4 pages]Dr. Lisa GrohskopfPneumococcal Vaccines
Introduction [9 pages]Dr. Katherine Poehling
Epidemiology of pneumococcal disease among U.S. children [21 pages]Mr. Ryan Gierke
Estimating the impact of higher-valency PCVs on pediatric outpatient ARI visits and antibiotic use [27 pages]Ms. Laura King
PCV20 Phase 2/3 study results among children [18 pages]Dr. Wendy Watson
Preliminary EtR (incl. GRADE) for PCV20 use in U.S. children [57 pages]Dr. Miwako Kobayashi
Workgroup considerations [12 pages]Dr. Miwako KobayashiFebruary 23, 2023
Welcome & Introductions
IntroductionDr. G Lee
Dr. M WhartonAgency Updates
Meningococcal Vaccines
Introduction [8 pages]Dr. Kathy Poehling
Epidemiology of meningococcal disease in the United States [17 pages]Ms. Amy Rubis
Pfizer pentavalent meningococcal vaccine [26 pages]Dr. Jason Maguire
Workgroup considerations [15 pages]Dr. Sam CrowePolio Vaccine
Introduction [2 pages]Dr. Oliver Brooks
Recommendations for Adult Polio Vaccination [29 pages]Dr. Sarah KiddRSV Vaccines – Pediatric/Maternal
Introduction [5 pages]Dr. S Long
Cost effectiveness analysis for nirsevimab – CDC model [51 pages]Dr. David Hutton
Cost effectiveness analysis for nirsevimab – Comparison to manufacturer model [25 pages]Dr. Ismael Ortega Sanchez
Evidence to Recommendations framework for nirsevimab [92 pages]Dr. Jefferson Jones
Clinical considerations for nirsevimab [16 pages]Dr. Jefferson Jones
Safety and Efficacy of RSV Bivalent PreF Maternal Vaccine [31 pages]Dr. Iona Munjal
Workgroup considerations [6 pages]Dr. Katherine Fleming-DutraRSV Vaccines – Adult
Introduction [8 pages]Dr. Camille Kotton
Cost effectiveness of the GSK and Pfizer vaccines (main CDC model) [37 pages]Dr. David Hutton
Comparison of cost effectiveness results of the main CDC model and each manufacturer model (GSK & Pfizer) [24 pages]Dr. Ismael Ortega Sanchez
EtR (incl. GRADE) for 2 vaccines (GSK & Pfizer) [90 pages]Dr. Michael Melgar
Vaccine policy questions (GSK & Pfizer) [2 pages]Dr. Michael MelgarChikungunya Vaccine
Introduction [7 pages]Dr. Beth Bell
Global epidemiology of chikungunya [12 pages]Dr. Susan Hills
Chikungunya in U.S. travelers [15 pages]Ms. Nicole Lindsey
Persistent arthralgia following chikungunya [21 pages]Ms. Nicole Lindsey
Workgroup considerations [4 pages]Ms. Nicole LindseyDengue Vaccines
Introduction [8 pages]Dr. W Chen
Takeda dengue vaccine (TAK-003) safety and efficacy [26 pages]Dr. Shibidas Biswal
Workgroup considerations [22 pages]Dr. Gabriela Paz-BaileyVaricella
Public health impact of 25 years of varicella vaccination in the United States [23 pages]Dr. Mona MarinFebruary 24, 2023
Welcome & Introductions
IntroductionDr. G Lee
Dr. M WhartonCOVID-19 Vaccines
Introduction [7 pages]Dr. Matthew Daley
COVID-19 vaccine safety updates: CDC [43 pages]Dr. Tom Shimabukuro
COVID-19 vaccine safety updates: FDA [17 pages]Dr. Richard Forshee
VaST summary [10 pages]Dr. Keipp Talbot
WG interpretation and summary [19 pages]Dr. Evelyn Twentyman
Updates on COVID-19 hospitalizations: COVID-NET [14 pages]Dr. Chris Taylor
Updates to COVID-19 vaccine effectiveness in the United States [29 pages]Dr. Amadea Britton
Considerations for transitioning to bivalent primary series [32 pages]Dr. Sara Oliver
Benefit/risk for COVID-19 vaccines [21 pages]Dr. Megan Wallace
COVID-19 vaccines: future directions [37 pages]Dr. Sara Oliver
							
					
							Last Reviewed:  February 24, 2023						Source: 	National Center for Immunization and Respiratory Diseases
					Facebook
        Twitter
        LinkedIn
        Syndicate homeACIP Home
Meeting Information
Committee Informationplus icon
Role of the ACIP in CDC’s Vaccine Recommendations
Charter
Economics Studies
Committee Membersplus icon
ACIP Membership Roster
Apply for ACIP Membership
Work Groupsplus icon
VaST Reportsplus icon
June 28, 2021
May 24, 2021
May 17, 2021
March 29, 2021
Recommendationsplus icon
Shared Clinical Decision-Making Recommendations
Evidence Based Recommendationsplus icon
About GRADE
Grade Evidence Tables
Evidence to Recommendations Frameworks Vaccines & ImmunizationsImmunization SchedulesVFC ResolutionsVaccine Information Statements (VISs)
  1600 Clifton Road, N.E., Mailstop A27
Atlanta, GA 30329-4027acip@cdc.gov


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue